SuperworthCytek Biosciences price to sales ratio CTKB
Market value divided by revenue over the last twelve months, since 2022.
- Today, Oct 23, 2026
- 3.5×
- 5-year median
- 4.0×
- Against its 5-year history
- 39th
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 1.6× to 14.6×
- Peer median
- 5.5×
Cytek Biosciences' price to sales ratio is 3.5× as of Oct 23, 2026.
That is below its 5-year median of 4.0×, close to the middle of its last 5 years.
Over that time it ranged from 1.6× in May 2025 to 14.6× in Aug 2022.
The median for 6 diagnostics and research stocks of a similar size is 5.5×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 3.5× | 2.2× | 3.7× |
| 2025 | 3.3× | 1.6× | 4.4× |
| 2024 | 4.1× | 3.1× | 6.8× |
| 2023 | 6.8× | 3.4× | 11.7× |
| 2022 | 8.9× | 8.8× | 14.6× |
Against its peers
Companies in Medical - Diagnostics & Research nearest Cytek Biosciences' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| CTKBCytek Biosciences | 3.5× |
| NRCNRC Health | 3.5× |
| CDNACareDx | 7.8× |
| VCYTVeracyte | 6.9× |
| BLLNBillionToOne | 12.8× |
| ICCCImmucell | 3.0× |
| LNTHLantheus | 4.2× |
| Peer median | 5.5× |
Where Cytek Biosciences ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Cytek Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.